H Gauthier1, M N Guilhaume1, F C Bidard1, J Y Pierga2, V Girre1, P H Cottu1, V Laurence1, A Livartowski1, L Mignot1, V Diéras3. 1. Department of Medical Oncology, Institut Curie, Paris, France. 2. Department of Medical Oncology, Institut Curie, Paris, France; University Paris Descartes, Paris. 3. Department of Medical Oncology, Institut Curie, Paris, France. Electronic address: veronique.dieras@curie.net.
Abstract
BACKGROUND: Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC). The aim of this study was to report the outcome of patients diagnosed with breast cancer MC and treated in single institution by a high-dose intrathecal methotrexate (MTX) regimen. METHODS: Ninety-one patients were diagnosed with breast cancer MC from 2000 to 2007. Intrathecal treatment was MTX 15 mg/day (days 1-5), hydrocortisone acetate (day 1) and oral folinic acid (days 1-5), repeated every 2 weeks. Patients and tumor characteristics were associated with the early clinical and biological outcome and with the overall survival (OS). RESULTS: The median survival was 4.5 months (range 0-53). In multivariate analysis, adverse prognostic factors at diagnosis were performance status >2 [P = 0.006, response rate (RR) = 0.33 (0.15-0.71)], more than three chemotherapy regimens before MC diagnosis [P = 0.03, RR = 0.40 (0.19-0.93)], negative hormone receptor status [P = 0.02, RR = 0.4 (0.19-0.90)] and high Cyfra 21-1 level [P = 0.048, RR = (0.09-0.99)]. Clinical progression after one cycle and biological response after two cycles were independently associated with OS [P < 0.001, RR = 0.09 (0.02-0.37) and P = 0.003, RR = 3.6 (1.5-8.5), respectively]. We propose a prognostic score in order to define three distinct groups of prognosis. CONCLUSIONS: MC presents a poor prognosis, but 1-year survival rate was 25%. This score may become a useful tool for treatment decision and clinical trials.
BACKGROUND:Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC). The aim of this study was to report the outcome of patients diagnosed with breast cancer MC and treated in single institution by a high-dose intrathecal methotrexate (MTX) regimen. METHODS: Ninety-one patients were diagnosed with breast cancer MC from 2000 to 2007. Intrathecal treatment was MTX 15 mg/day (days 1-5), hydrocortisone acetate (day 1) and oral folinic acid (days 1-5), repeated every 2 weeks. Patients and tumor characteristics were associated with the early clinical and biological outcome and with the overall survival (OS). RESULTS: The median survival was 4.5 months (range 0-53). In multivariate analysis, adverse prognostic factors at diagnosis were performance status >2 [P = 0.006, response rate (RR) = 0.33 (0.15-0.71)], more than three chemotherapy regimens before MC diagnosis [P = 0.03, RR = 0.40 (0.19-0.93)], negative hormone receptor status [P = 0.02, RR = 0.4 (0.19-0.90)] and high Cyfra 21-1 level [P = 0.048, RR = (0.09-0.99)]. Clinical progression after one cycle and biological response after two cycles were independently associated with OS [P < 0.001, RR = 0.09 (0.02-0.37) and P = 0.003, RR = 3.6 (1.5-8.5), respectively]. We propose a prognostic score in order to define three distinct groups of prognosis. CONCLUSIONS: MC presents a poor prognosis, but 1-year survival rate was 25%. This score may become a useful tool for treatment decision and clinical trials.
Authors: Nicholas B Figura; Victoria T Rizk; Avan J Armaghani; John A Arrington; Arnold B Etame; Hyo S Han; Brian J Czerniecki; Peter A Forsyth; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2019-06-17 Impact factor: 4.872
Authors: Lindsay Angus; John W M Martens; Martin J van den Bent; Peter A E Sillevis Smitt; Stefan Sleijfer; Agnes Jager Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: Anna Niwińska; Katarzyna Pogoda; Wojciech Michalski; Michał Kunkiel; Agnieszka Jagiełło-Gruszfeld Journal: J Neurooncol Date: 2018-02-12 Impact factor: 4.130
Authors: A Comte; W Jdid; M N Guilhaume; I Kriegel; S Piperno-Neumann; V Dieras; T Dorval; J Y Pierga; P H Cottu; L Mignot; F C Bidard Journal: J Neurooncol Date: 2013-09-17 Impact factor: 4.130
Authors: E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain Journal: J Neurooncol Date: 2013-03-01 Impact factor: 4.130
Authors: Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain Journal: J Neurooncol Date: 2014-01-28 Impact factor: 4.130